MedTrace Logo

Vigabatrin for Treatment of Cocaine Dependence

NCT00611130 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2016-04-13

Study results available
· View outcomes & findings →

Summary

The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.

Conditions

  • Cocaine Dependence

Interventions

DRUG

vigabatrin

Tablets twice a day for 9 weeks

DRUG

placebo

tablets twice daily for 9 weeks

Sponsors & Collaborators

Principal Investigators

  • Eugene Somoza, MD, PhD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-05-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00611130 on ClinicalTrials.gov